Renal Insufficiency, Chronic
"Renal Insufficiency, Chronic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Conditions in which the KIDNEYS perform below the normal level for more than three months. Chronic kidney insufficiency is classified by five stages according to the decline in GLOMERULAR FILTRATION RATE and the degree of kidney damage (as measured by the level of PROTEINURIA). The most severe form is the end-stage renal disease (CHRONIC KIDNEY FAILURE). (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002)
| Descriptor ID |
D051436
|
| MeSH Number(s) |
C12.777.419.780.750 C13.351.968.419.780.750
|
| Concept/Terms |
Renal Insufficiency, Chronic- Renal Insufficiency, Chronic
- Chronic Renal Insufficiencies
- Renal Insufficiencies, Chronic
- Chronic Renal Insufficiency
- Kidney Insufficiency, Chronic
- Chronic Kidney Insufficiency
- Chronic Kidney Insufficiencies
- Kidney Insufficiencies, Chronic
Chronic Kidney Diseases- Chronic Kidney Diseases
- Chronic Kidney Disease
- Disease, Chronic Kidney
- Diseases, Chronic Kidney
- Kidney Disease, Chronic
- Kidney Diseases, Chronic
- Chronic Renal Diseases
- Chronic Renal Disease
- Disease, Chronic Renal
- Diseases, Chronic Renal
- Renal Disease, Chronic
- Renal Diseases, Chronic
|
Below are MeSH descriptors whose meaning is more general than "Renal Insufficiency, Chronic".
Below are MeSH descriptors whose meaning is more specific than "Renal Insufficiency, Chronic".
This graph shows the total number of publications written about "Renal Insufficiency, Chronic" by people in this website by year, and whether "Renal Insufficiency, Chronic" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2006 | 2 | 0 | 2 |
| 2008 | 3 | 0 | 3 |
| 2009 | 3 | 1 | 4 |
| 2010 | 7 | 2 | 9 |
| 2011 | 6 | 0 | 6 |
| 2012 | 7 | 4 | 11 |
| 2013 | 21 | 3 | 24 |
| 2014 | 18 | 4 | 22 |
| 2015 | 20 | 3 | 23 |
| 2016 | 11 | 1 | 12 |
| 2017 | 17 | 6 | 23 |
| 2018 | 15 | 3 | 18 |
| 2019 | 20 | 1 | 21 |
| 2020 | 22 | 4 | 26 |
| 2021 | 24 | 3 | 27 |
| 2022 | 38 | 1 | 39 |
| 2023 | 8 | 0 | 8 |
To return to the timeline,
click here.
Below are the most recent publications written about "Renal Insufficiency, Chronic" by people in Profiles.
-
Design of the COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint study (CONFIDENCE). Nephrol Dial Transplant. 2023 03 31; 38(4):894-903.
-
Effects of finerenone in people with chronic kidney disease and type 2 diabetes are independent of HbA1c at baseline, HbA1c variability, diabetes duration and insulin use at baseline. Diabetes Obes Metab. 2023 06; 25(6):1512-1522.
-
Kidney outcomes with finerenone: an analysis from the FIGARO-DKD study. Nephrol Dial Transplant. 2023 02 13; 38(2):372-383.
-
Effects of canagliflozin on liver steatosis and fibrosis markers in patients with type 2 diabetes and chronic kidney disease: A post hoc analysis of the CREDENCE trial. Diabetes Obes Metab. 2023 05; 25(5):1413-1418.
-
Finerenone and effects on mortality in chronic kidney disease and type 2 diabetes: a FIDELITY analysis. Eur Heart J Cardiovasc Pharmacother. 2023 02 02; 9(2):183-191.
-
Albuminuria and Heart?Failure: JACC State-of-the-Art Review. J Am Coll Cardiol. 2023 01 24; 81(3):270-282.
-
Navigating the Dobbs versus Jackson America for Patients with CKD and Kidney Transplants. J Am Soc Nephrol. 2023 02 01; 34(2):201-204.
-
2022 Clinical Practice Guideline Update for Diabetes Management of Chronic Kidney Disease: An Important First Step, More Work to Do. Ann Intern Med. 2023 03; 176(3):417-418.
-
Pre-operative kidney biomarkers and risks for death, cardiovascular and chronic kidney disease events after cardiac surgery: the TRIBE-AKI study. J Cardiothorac Surg. 2022 Dec 25; 17(1):338.
-
Finerenone efficacy in patients with chronic kidney disease, type 2 diabetes and atherosclerotic cardiovascular disease. Eur Heart J Cardiovasc Pharmacother. 2022 12 15; 9(1):85-93.